Amanote Research

Amanote Research

    RegisterSign In

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

PLoS ONE - United States
doi 10.1371/journal.pone.0038783
Full Text
Open PDF
Abstract

Available in full text

Categories
Multidisciplinary
Date

June 28, 2012

Authors
Foluso O. AdemuyiwaWiam BsharaKristopher AttwoodCarl MorrisonStephen B. EdgeChristine B. AmbrosoneTracey L. O’ConnorEllis G. LevineAnthony MiliottoErika RitterGerd RitterSacha GnjaticKunle Odunsi
Publisher

Public Library of Science (PLoS)


Related search

A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression

Thyroid
MedicineEndocrinologyMetabolismDiabetes
2014English

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Triple Negative Breast Cancer: Heterogenous Disease

REVIEWS IN ONCOLOGY
2013English

Immunohistochemical Expression and Clinicopathological Assessment of the Cancer Testis Antigens NY‑ESO‑1 and MAGE‑A4 in High‑grade Soft‑tissue Sarcoma

Oncology Letters
Cancer ResearchOncology
2019English

FZD7 in Triple Negative Breast Cancer Cells

2011English

Role of Immunotherapy in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Rad51 Supports Triple Negative Breast Cancer Metastasis.

Oncotarget
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy